Business
    Next Score View the next score

    Mass. Movers

    Alnylam cites charge for earnings loss

    Alnylam cited a one-time charge for its net loss.
    istockphoto.com
    Alnylam cited a one-time charge for its net loss.
    Advertisement

    Alnylam Pharmaceuticals Inc. reported a fourth-quarter net loss of $63.2 million, or $1.20 per share, compared with a loss of $14.3 million, or 33 cents, in the same period last year. For the year, the net loss was $106 million, or $2.11 per share, compared with a loss of $57.6 million, or $1.36, for the prior year. The Cambridge biotech cited a one-time charge of $65 million related to the restructuring of its licensing agreement with Tekmira Pharmaceuticals Corp. for the loss.